BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 9140267)

  • 1. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.
    Levin B; Hess K; Johnson C
    Arch Intern Med; 1997 May; 157(9):970-6. PubMed ID: 9140267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of fecal occult-blood tests for colorectal-cancer screening.
    Allison JE; Tekawa IS; Ransom LJ; Adrain AL
    N Engl J Med; 1996 Jan; 334(3):155-9. PubMed ID: 8531970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population colorectal cancer screening with fecal occult blood test.
    Rennert G; Rennert HS; Miron E; Peterburg Y
    Cancer Epidemiol Biomarkers Prev; 2001 Nov; 10(11):1165-8. PubMed ID: 11700264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.
    Greenberg PD; Bertario L; Gnauck R; Kronborg O; Hardcastle JD; Epstein MS; Sadowski D; Sudduth R; Zuckerman GR; Rockey DC
    Am J Gastroenterol; 2000 May; 95(5):1331-8. PubMed ID: 10811348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal occult blood testing: clinical value and limitations.
    Simon JB
    Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measuring the quality of colorectal cancer screening: the importance of follow-up.
    Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
    Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periodic health examination, 1994 update: 2. Screening strategies for colorectal cancer. Canadian Task Force on the Periodic Health Examination.
    Solomon MJ; McLeod RS
    CMAJ; 1994 Jun; 150(12):1961-70. PubMed ID: 7980760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colocare self-test versus Hemoccult II Sensa for fecal occult blood testing.
    Foliente RL; Wise GR; Collen MJ; Abdulian JD; Chen YK
    Am J Gastroenterol; 1995 Dec; 90(12):2160-3. PubMed ID: 8540507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer screening through detection of fecal occult blood in a controlled health zone.
    Tárraga P; García-Olmo D; Celada A; García-Molinero Mf; Divison JA; Casado C
    Rev Esp Enferm Dig; 1999 May; 91(5):335-44. PubMed ID: 10362875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Performance of the Hemoccult test in the screening of colorectal cancer and adenoma. Results of 5 screening campaigns in Saône-et-Loire].
    Tazi MA; Faivre J; Lejeune C; Benhamiche AM; Dassonville F
    Gastroenterol Clin Biol; 1999 May; 23(5):475-80. PubMed ID: 10429850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal occult blood testing: comparative evaluation of a two-hole versus a three-hole single slide test.
    Porschen R; Kruis W; Strohmeyer G
    Hepatogastroenterology; 1993 Apr; 40(2):191-3. PubMed ID: 8509054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a repeat television-advertised mass screening program for colorectal cancer using fecal occult blood tests.
    McGarrity TJ; Long PA; Peiffer LP
    Am J Gastroenterol; 1990 Mar; 85(3):266-70. PubMed ID: 2309678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
    Sharma VK; Corder FA; Fancher J; Howden CW
    Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening.
    Kershenbaum A; Flugelman A; Lejbkowicz F; Arad H; Rennert G
    Eur J Cancer; 2013 Mar; 49(4):923-30. PubMed ID: 23099005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.